Aligos Therapeutics Inc Ordinary Shares ALGS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
Trading Information
- Previous Close Price
- $2.57
- Day Range
- $2.03–2.66
- 52-Week Range
- $2.03–13.61
- Bid/Ask
- $1.61 / $2.63
- Shares Outstanding
- 6.25M
- Market Cap
- $13.50M
- Volume/Avg
- 283,603 / 55,984
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 82
- Website
- https://www.aligos.com
Valuation
Metric | ALGS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.20 |
Price/Sales | 0.67 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ALGS |
|---|---|
Quick Ratio | 1.59 |
Current Ratio | 1.77 |
Interest Coverage | — |
Quick Ratio
ALGS
Profitability
Metric | ALGS |
|---|---|
Return on Assets (Normalized) | −90.39% |
Return on Equity (Normalized) | −169.79% |
Return on Invested Capital (Normalized) | −150.13% |
Return on Assets
ALGS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Yv>P<VH | LOCK|?Q?JQ | $139B | |||
| Moderna Inc MRNA | LOCK|!BkpLJ | LOCK|%>@ | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!ND>PP | LOCK|p^Yw | $95B | |||
| argenx SE ADR ARGX | LOCK|!gzS@l? | LOCK|^&? | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!c%ygw# | LOCK|?f | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|kjDrR@J> | LOCK|^<Z#? | $31B | |||
| Incyte Corp INCY | LOCK|MCx#wD | LOCK|#@$ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|Jc^qq> | LOCK|Zt | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|ZH^<&@< | LOCK|^&df | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|!@Q^jl | LOCK|#w | $16B |
United States